Cipla's scion leaves company for 'new horizons'
This article was originally published in Scrip
Executive Summary
Cipla's scion Kamil Hamied, son of vice-chair MK Hamied and nephew of chairman, Dr Yusuf Hamied, is leaving the Indian generic giant.
You may also be interested in...
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, an investment banker tells Scrip.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.